DataVXSmallPaper
journal article·2026-06

An mRNA Tumor Nanovaccine Expressing Tumor Antigen Fused With Angiotensin II Facilitates Type 1 Conventional Dendritic Cell‐Mediated Anti‐Tumor Immunity

Chunyuan Xie, Hui Guo, Chunlei Dai, Liying Wang, Ruhui Yao, Lei Cui, Xinru You, Zining Wang, Hongxia Zhang, Huanling Zhang, Lin Li, Tiantian Wang, Zixuan Guo, Yanxun Lin, Jiahong Yi, Jiaxin Wu, Ju Xue, Huan Jin, Yue Zhao, Zhiming Wu, Jun Wu, Xiaojun Xia

Small· Volume 22· Issue 32
Publisher page
Source abstract

Abstract

ABSTRACT mRNA‐based tumor vaccines have shown great potential as a promising immunotherapeutic approach with encouraging preclinical and clinical results. However, how to enhance the antigen presentation efficiency of mRNA‐encoded tumor antigens and the intensity of vaccine‐induced CD8 + T cell response remains a great challenge. In this study, an antigen‐angiotensin II (ANG II) fusion mRNA nanovaccine that can enhance the immunogenicity of tumor antigens to promote CD8 + T cell immunity for effective tumor inhibition is developed. Furthermore, this mRNA nanovaccine is delivered by lipid nanoparticles (LNPs) composed of cationic lipid‐like material C1 and L‐phenylalanine‐based poly (ester amide) 8p4, which promotes the maturation of dendritic cells (DCs) and increases the type 1 conventional DC (cDC1) subpopulation, together enhancing the antigen presentation function of DCs for eliciting potent antigen‐specific CD8 + T cell response. Vaccination with the antigen‐ANG II mRNA nanovaccine expressing different tumor antigens effectively inhibited tumor growth on multiple mouse tumor models, which was greatly compromised in the cDC1‐deficient Batf3 −/− mice. Overall, this work provides an antigen‐ANG II fusion mRNA tumor nanovaccine platform with remarkable antitumor efficacy via triggering cDC1‐mediated CD8 + T cell response.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou China

Jiangxi Provincial Key Laboratory for Precision Pathology and Intelligent Diagnosis, Department of Pathology and Institute of Molecular Pathology The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China

Bioscience and Biomedical Engineering Thrust The Hong Kong University of Science and Technology (Guangzhou) Guangzhou China

Center For Nanomedicine and Department of Anesthesiology Harvard Medical School, Brigham and Women's Hospital Boston Massachusetts USA

Department of Pathology School of Basic Medical Sciences Nanfang Hospital Southern Medical University Guangzhou Guangdong China

Guangdong Province Key Laboratory of Molecular Tumor Pathology Guangzhou China

Guangzhou National Laboratory Guangzhou China

Department of Urology Sun Yat‐sen University Cancer Center Guangzhou China

Hainan Academy of Medical Sciences Hainan Medical University Haikou China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Guangdong Province

References (54)

Show source-provided references
1. 10.1038/s41571-020-00460-210.1038/s41571-020-00460-2 ↗
2. 10.1038/nri.2017.13110.1038/nri.2017.131 ↗
3. 10.1038/s41577-019-0210-z10.1038/s41577-019-0210-z ↗
4. 10.1016/j.cell.2019.02.00510.1016/j.cell.2019.02.005 ↗
5. 10.1126/science.116420610.1126/science.1164206 ↗
6. 10.1016/j.immuni.2021.08.02610.1016/j.immuni.2021.08.026 ↗
7. 10.1038/s41541-023-00760-510.1038/s41541-023-00760-5 ↗
8. 10.1016/j.immuni.2024.03.01510.1016/j.immuni.2024.03.015 ↗
9. 10.1038/nbt.243610.1038/nbt.2436 ↗
10. 10.1016/j.biomaterials.2020.11985210.1016/j.biomaterials.2020.119852 ↗
11. 10.1016/j.biomaterials.2020.12043110.1016/j.biomaterials.2020.120431 ↗
12. 10.1016/j.immuni.2021.11.00110.1016/j.immuni.2021.11.001 ↗
13. 10.1073/pnas.200519111810.1073/pnas.2005191118 ↗
14. 10.1038/s41587-019-0247-310.1038/s41587-019-0247-3 ↗
15. 10.1038/s41587-022-01294-210.1038/s41587-022-01294-2 ↗
16. 10.1016/j.ymthe.2021.03.00210.1016/j.ymthe.2021.03.002 ↗
17. 10.1111/imm.1377710.1111/imm.13777 ↗
18. 10.1002/advs.20230041810.1002/advs.202300418 ↗
19. 10.1182/blood-2007-03-08099410.1182/blood-2007-03-080994 ↗
20. 10.1681/ASN.200703029010.1681/ASN.2007030290 ↗
21. 10.1096/fj.02-0755fje10.1096/fj.02-0755fje ↗
22. 10.1016/j.addr.2021.11400810.1016/j.addr.2021.114008 ↗
23. 10.1096/fj.13-24348510.1096/fj.13-243485 ↗
24. 10.1182/blood-2003-10-355910.1182/blood-2003-10-3559 ↗
25. 10.1002/emmm.20100008010.1002/emmm.201000080 ↗
26. 10.1084/jem.2007065710.1084/jem.20070657 ↗
27. 10.1152/physrev.00038.201710.1152/physrev.00038.2017 ↗
28. 10.1172/JCI12747110.1172/JCI127471 ↗
29. 10.1038/s41551-018-0284-010.1038/s41551-018-0284-0 ↗
30. 10.1016/j.immuni.2012.03.01310.1016/j.immuni.2012.03.013 ↗
31. 10.1126/scitranslmed.abf099210.1126/scitranslmed.abf0992 ↗
32. 10.1016/j.ccell.2023.02.01610.1016/j.ccell.2023.02.016 ↗
33. 10.1016/j.immuni.2023.08.01410.1016/j.immuni.2023.08.014 ↗
34. 10.1016/j.ymthe.2017.11.00910.1016/j.ymthe.2017.11.009 ↗
35. 10.1038/nature1400110.1038/nature14001 ↗
36. 10.1038/s41577-023-00937-y10.1038/s41577-023-00937-y ↗
37. 10.1093/annonc/mdx23710.1093/annonc/mdx237 ↗
38. 10.1126/science.adh456710.1126/science.adh4567 ↗
39. 10.1074/jbc.M90893119910.1074/jbc.M908931199 ↗
40. 10.1152/ajpregu.90521.200810.1152/ajpregu.90521.2008 ↗
41. 10.1161/HYPERTENSIONAHA.114.0414710.1161/HYPERTENSIONAHA.114.04147 ↗
42. 10.1111/imm.1225510.1111/imm.12255 ↗
43. 10.1038/s41586-020-2611-310.1038/s41586-020-2611-3 ↗
44. 10.1016/j.immuni.2016.03.01210.1016/j.immuni.2016.03.012 ↗
45. 10.1038/s41571-024-00859-110.1038/s41571-024-00859-1 ↗
46. 10.1126/science.adn908310.1126/science.adn9083 ↗
47. 10.1126/sciimmunol.add481710.1126/sciimmunol.add4817 ↗
48. 10.1002/advs.20230583210.1002/advs.202305832 ↗
49. 10.1038/s41392-024-01838-910.1038/s41392-024-01838-9 ↗
50. 10.1016/j.jconrel.2025.11389210.1016/j.jconrel.2025.113892 ↗
51. 10.1038/s41590-022-01160-y10.1038/s41590-022-01160-y ↗
52. StraPep: A Structure Database of Bioactive Peptides
53. 10.1016/j.xpro.2024.10308710.1016/j.xpro.2024.103087 ↗
54. 10.1016/j.ymthe.2025.09.03210.1016/j.ymthe.2025.09.032 ↗